<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01335165</url>
  </required_header>
  <id_info>
    <org_study_id>TT30-PNH-002</org_study_id>
    <nct_id>NCT01335165</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)</brief_title>
  <official_title>A Phase 1, Single Ascending Dose Study of the Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to understand the safety, pharmacokinetics and
      pharmacodynamics of a single dose of TT30 (ALXN1102 and ALXN1103 formulations) when given IV
      (through a vein) or SC (under the skin) to patients with PNH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, single-dose, dose-escalation study to assess the safety, tolerability,
      PK, PD, and immunogenicity of TT30 given as an IV infusion and as a SC injection in subjects
      with PNH or evidence of circulating PNH cells.

      Eligible subjects with PNH will be vaccinated with meningococcal vaccine at least two weeks
      prior to dosing (if not previously vaccinated or if revaccination is required).

      On study day 1, the subject will receive the single dose of TT30 as an IV infusion over 60
      minutes or as a SC injection, and be followed with additional study evaluations over the next
      59 days.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inability to reach enrollment as planned
  </why_stopped>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the safety and tolerability of a single dose of TT30.</measure>
    <time_frame>60 days</time_frame>
    <description>Safety and tolerability will be evaluated in all subjects by physical exam, vital signs, ECGs, laboratory changes over time, adverse events, and antibody development.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize PK, PD and immunogenicity of a single dose of TT30.</measure>
    <time_frame>60 days</time_frame>
    <description>Immunogenicity will be will be assessed using standard measures for these parameters. PK and PD will be assessed by using standard measures, including reticulocyte count and lactate dehydrogenase (LDH) levels.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Paroxysmal Nocturnal Hemoglobinuria (PNH)</condition>
  <arm_group>
    <arm_group_label>TT30 (ALXN1102 Formulation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV: 0.1, 0.3, and 1.0 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TT30 (ALXN1103 Formulation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV: 3.0, 6.0, and 10.0 mg/kg
SC: 1.0 and 3.0 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALXN1102</intervention_name>
    <description>Single Ascending Dose IV</description>
    <arm_group_label>TT30 (ALXN1102 Formulation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALXN1103</intervention_name>
    <description>Single Ascending Dose IV or SC</description>
    <arm_group_label>TT30 (ALXN1103 Formulation)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals at least 18 years of age with a diagnosis of PNH &amp; vaccination against
             meningococcus.

        Exclusion Criteria:

          -  Abnormal renal or liver function

          -  History of meningococcal disease

          -  History of Guillain-Barre syndrome

          -  Known infection with HIV or Hepatitis B or C

          -  History of thrombotic events
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bill Lundberg, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alexion Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology and Blood Transfusion / Institut Hematologie a krevní transfuze</name>
      <address>
        <city>U nemocnice 1</city>
        <state>Prague 2</state>
        <zip>128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federico II University of Naples</name>
      <address>
        <city>Via Pansini 5</city>
        <state>Naples</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Centre</name>
      <address>
        <city>Dębinki 7</city>
        <state>Gdańsk</state>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>Denmark Hill</city>
        <state>London</state>
        <zip>SE5 9RS UK</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2011</study_first_submitted>
  <study_first_submitted_qc>April 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2011</study_first_posted>
  <last_update_submitted>May 21, 2014</last_update_submitted>
  <last_update_submitted_qc>May 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PNH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

